Stryker Corporation $SYK Position Raised by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 103.6% during the third quarter, HoldingsChannel reports. The firm owned 28,206 shares of the medical technology company’s stock after purchasing an additional 14,355 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Stryker were worth $7,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Mitchell Mcleod Pugh & Williams Inc. grew its position in Stryker by 1.2% during the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock valued at $880,000 after buying an additional 31 shares during the period. Community Bank & Trust Waco Texas raised its position in Stryker by 2.3% in the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after acquiring an additional 31 shares during the period. Cornerstone Financial Management LLC boosted its stake in Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. NWF Advisory Services Inc. boosted its stake in Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after acquiring an additional 33 shares during the last quarter. Finally, Harold Davidson & Associates Inc. boosted its stake in Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after acquiring an additional 34 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. TD Cowen decreased their price target on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a research note on Tuesday, September 22nd. Citigroup dropped their price objective on Stryker from $399.00 to $360.00 and set a “buy” rating on the stock in a research note on Thursday, September 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. Citizens Jmp decreased their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Price Performance

Shares of NYSE:SYK opened at $306.50 on Tuesday. The firm has a market capitalization of $117.56 billion, a PE ratio of 31.76, a P/E/G ratio of 1.98 and a beta of 0.78. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $295.95 and a two-hundred day moving average price of $326.09. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Activity at Stryker

In other Stryker news, Director Ronda Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.